NEKTAR THERAPEUTICS (NKTR)
US6402681083 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 35.28M | 88.20M | 25.20M | 199.00M | 96.40M | |||
| Marketable Securities | 268.34M | 416.80M | 708.70M | 862.90M | 1.23B | |||
| Receivables | 1.21M | 6.00M | 22.50M | 38.90M | 36.80M | |||
| Inventories | 16.10M | 19.20M | 15.80M | 15.30M | 12.70M | |||
| Other Current Assets | 9.78M | 15.80M | 23.30M | 21.90M | 47.20M | |||
| Total Current Assets | 330.70M | 546.00M | 795.60M | 1.14B | 1.42B | |||
| Non-Current Assets | ||||||||
| PPE Net | 36.86M | 85.90M | 177.50M | 186.10M | 199.20M | |||
| Investments And Advances | 25.82M | 0.00 | 64.80M | 136.70M | 279.10M | |||
| Goodwill | 0.00 | 76.50M | 76.50M | 76.50M | 76.50M | |||
| Other Non-Current Assets | 4.64M | 2.20M | 2.70M | 1.50M | 1.00M | |||
| Total Non-Current Assets | 67.33M | 164.60M | 321.60M | 400.80M | 555.80M | |||
| TOTAL ASSETS | 398.03M | 710.60M | 1.12B | 1.54B | 1.98B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 0.00 | 248.70M | |||
| Accrued Expenses | 41.42M | 55.20M | 75.50M | 93.50M | 79.50M | |||
| Accounts Payable | 9.85M | 13.00M | 9.70M | 22.10M | 19.20M | |||
| Other Current Liabilities | N/A | N/A | N/A | 100.00K | 6.40M | |||
| Total Current Liabilities | 51.27M | 68.20M | 85.20M | 115.80M | 353.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 215.78M | 275.80M | 352.50M | 345.70M | 218.10M | |||
| Total Non-Current Liabilities | 215.78M | 275.80M | 352.50M | 345.70M | 218.10M | |||
| TOTAL LIABILITIES | 267.05M | 344.00M | 437.70M | 461.50M | 572.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -3.48B | -3.20B | -2.83B | -2.31B | -1.86B | |||
| Additional Paid In Capital | 3.61B | 3.57B | 3.52B | 3.39B | 3.27B | |||
| Common Shares | 19.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 80.00K | -6.90M | -4.20M | -2.30M | -1.00M | |||
| Shares Outstanding | 191.38M | 188.60M | 185.50M | 180.10M | 176.50M | |||
| Tangible Book Value per Share | 0.68 | 1.54 | 3.25 | 5.56 | 7.53 | |||
| Total Shareholders' Equity | 130.99M | 366.60M | 679.50M | 1.08B | 1.41B | |||
| TOTAL LIABILITIES AND EQUITY | 398.03M | 710.60M | 1.12B | 1.54B | 1.98B | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 6.45 | 8.01 | 9.34 | 9.83 | 4.02 | |||
| Return On Assets (ROA) | -69.36% | -51.82% | -46.89% | -28.88% | -22.29% | |||
| Return On Equity (ROE) | -210.75% | -100.44% | -77.09% | -41.25% | -31.36% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD